Global Hematopoietic Stem Cell Transplantation Market to Reach USD 15 Billion by 2033 at a 8% of CAGR, Driven by Rising Leukemia and Lymphoma Cases

Hematopoietic Stem Cell Transplantation Market

The global hematopoietic stem cell transplantation market is expected to witness significant growth, reaching a market value of USD 15 Billion by 2033. This comes as the market, valued at USD 7 Billion in 2023, is projected to grow at a CAGR of 8% from 2023 to 2033, according to a new analysis by Future Market Insights.

The robust growth forecast is attributed to the increasing prevalence of leukemia and lymphoma, which is driving demand for hematopoietic stem cell transplantation (HSCT) treatments. HSCT has emerged as a vital option for treating these and other hematological malignancies, offering the potential to restore healthy blood cells and immune function.

With the rising burden of cancer worldwide, the HSCT industry is expected to expand as healthcare providers focus on improving outcomes for patients undergoing stem cell transplants. Advancements in transplant technology, coupled with an increasing number of clinical trials exploring innovative therapies, are expected to further boost market growth during the forecast period.

This upward trend highlights the critical role of hematopoietic stem cell transplants in addressing life-threatening diseases, paving the way for new opportunities within the healthcare sector.

According to the Centers for Disease Control and Prevention (CDC), about 45,360 persons were diagnosed with leukemia in the United States in 2013, resulting in 23,549 deaths (13,625 men and 9,924 women). In accordance with the same source, men are more likely than women to have the illness. Leukemia contributes to approximately 3% of novel cancer cases.

Hematopoietic stem cell transplantation is a process in which multipotent hematopoietic stem cells are transferred into the patient from peripheral blood cells, bone marrow, or umbilical cord blood.

Lymphoma (Hodgkin and non-Hodgkin), leukemia, multiple myeloma, thalassemia, sickle cell anemia, and osteoporosis are all widely treated by hematopoietic stem cell transplantation. It has two transplantation sources: autologous (using stem cells from the patient’s own body) and allogeneic (using stem cells from a donor’s body).

Market Competition

Key players in the hematopoietic stem cell transplantation market are Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Sanofi, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio and Talaris Therapeutics.

Recent Developments:

• In December 2022, despite missing the primary endpoint, Takeda’s Phase 3 AURORA study shows that maribavir has a clinically meaningful and long-lasting effect on Cytomegalovirus (CMV) infection in hematopoietic stem cell transplant patients.
• In October 2022, Regen BioPharma, Inc. announced the filing of a provisional patent application with the USPTO titled “Enhancement of T Cell Homing to Tumors through Augmentation of Chemokine Responsiveness and Activation Dependent Chemokine Secretion” with the US Patent and Trademark Office.
• In November 2022, Lonza, a trusted partner in the pharmaceutical, biotech, and nutraceutical industries, introduced an innovative new capsule solution for enteric drug administration. The Capsugel® EnprotectTM capsule does not dissolve in the stomach and releases its contents only in the intestine. By eliminating the need for extra capsule coating or sealing, Capsugel® EnprotectTM capsules greatly simplify the medicinal product production process.
• In November 2021, Taiga Biotechnologies, a cell-based immunotherapy company, announced today that the first site in Croatia has completed the site initiation session for the TBX-2400-01 clinical trial, a Phase 1/2 study to evaluate the safety and early efficacy of TBX-2400 in acute myeloid leukemia (AML) and myelofibrosis patients undergoing hematopoietic stem cell transplant (HSCT)

Key Companies Profiled

• Pluristem Therapeutics Inc.
• CellGenix GmbH
• Regen Biopharma Inc.
• Lonza Group
• Sanofi
• Taiga Biotechnologies, Inc.
• Takeda Pharmaceutical Company Limited
• Escape Therapeutics, Inc.
• Bluebird Bio
• Talaris Therapeutics

A Full Report Overview

Key Segments Profiled in the Hematopoietic Stem Cell Transplantation Market Industry Survey

By Transplant Type:

• Allogeneic
• Autologous

By Indication:

• Acute Myeloid Leukemia
• Acute Lymphoblastic Leukemia
• Hodgkin Lymphoma
• Non-Hodgkin Lymphoma
• Multiple Myeloma
• Other Non-Malignant Disorders

By Application:

• Bone Marrow Transplant
• Peripheral Blood Stem Cells Transplant
• Cord Blood Transplant

Hematopoietic Stem Cell Transplantation Market by Region:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa (MEA)

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube